Indeed, the severity of non-motor symptoms decreased during the week 3 visit, with a more pronounced reduction in the KD group
Sublingual formulations : Designed for better absorption under the tongue
I, think its very interesting because they obviously have a very strong position in the incretin space and specifically for treatment of obesity and other related disease
Why Standardizing Decision-Making Matters The real question isn't "What dose should we use?" It's, "How do we create a safe, compliant process?" That looks like: Written protocols Clear eligibility criteria Strong informed consent forms Set follow-up checks Adverse event reporting Staff training Standard workflows protect your patients, your providers, and your spa
These letters were mailed July 31, 2025 (30 days prior to the change)
The PRegnancy Outcomes using continuous glucose monitoring TEChnology in pregnant women with early-onset Type 2 diabetes (PROTECT) trial will examine whether CGM use is effective for improving TIRp and reducing neonatal care admission or perinatal death (ISRCTN12804317)
